PTPN22 Inhibitors for Solid Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapies have limited effectiveness due to the suppressive role of PTPN22 in T cell receptor signaling, which hampers antitumor immune responses, and the potential of PTPN22 in the tumor microenvironment has not been well characterized.
Innovation Solution
Targeting PTPN22 with genetic ablation or pharmacologic inhibition, specifically using small molecule inhibitors like LTV1 and L-1, to enhance antitumor immune responses and synergize with checkpoint immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PTPN22 is inhibited to enhance T cell receptor signaling, then antitumor immune responses are augmented, but autoimmune disease risk increases
Solution Approach 1:
The patent applies local quality by using small molecule inhibitors that selectively target PTPN22 in the tumor microenvironment rather than systemically inhibiting it throughout the body. This localized approach enhances antitumor immunity while minimizing systemic autoimmune effects. The inhibitors are designed to accumulate preferentially in tumor tissues where they modulate PTPN22 activity in antigen-presenting cells and tumor-infiltrating lymphocytes.
Solution Approach 2:
The patent employs parameter changes by developing reversible inhibitors with tunable binding affinity to PTPN22. By adjusting the inhibition constant (Ki) and dosing regimens, the patent optimizes the balance between enhancing T cell activation for antitumor responses and maintaining sufficient PTPN22 activity to prevent autoimmune pathology. This dose-dependent modulation allows therapeutic window optimization.
2Productivity
If PTPN22 is genetically ablated to maximize immune activation, then tumor suppression is enhanced, but systemic immune dysregulation occurs
Solution Approach 1:
The patent extracts the harmful suppressive function of PTPN22 specifically from the tumor microenvironment using targeted inhibitors, rather than completely removing PTPN22 systemically through genetic ablation. This selective extraction of PTPN22 inhibitory activity in tumor tissues achieves maximal antitumor efficacy while preserving systemic immune homeostasis maintained by PTPN22 in non-tumor tissues.
Solution Approach 2:
The patent introduces small molecule inhibitors as intermediaries that temporarily and reversibly block PTPN22 function in the tumor microenvironment. These intermediary molecules provide controlled, reversible inhibition compared to permanent genetic ablation, allowing dynamic adjustment of PTPN22 activity to achieve tumor suppression while maintaining systemic immune regulation through endogenous PTPN22 in healthy tissues.
3Ease of operation
If conventional immunotherapies are used alone, then treatment simplicity is maintained, but response rates remain limited
Solution Approach 1:
The patent merges PTPN22 inhibition with existing immunotherapy approaches such as checkpoint inhibitors and adoptive T cell therapies. By combining PTPN22 inhibitors that enhance T cell receptor signaling with checkpoint blockers that release inhibitory signals, the patent creates synergistic effects that overcome resistance to single-agent therapies and significantly improve response rates while maintaining relatively simple administration protocols.
Data Source
AI summary
Described are methods of treating solid cancers in a subject. The methods comprise the steps of administering to the subject having the solid cancer or prone of getting the solid cancer an antagonist of PTPN22, or the functional part of PTPN22, and treating the solid cancer. Methods comprising use of other anticancer agents and adjuvants in conjunction with PTPN22 inhibitors are also provided.